What influences clinicians' decisions about ADHD medication? Initial data from the Influences on Prescribing for ADHD Questionnaire (IPAQ)

European Child and Adolescent Psychiatry

Volumn 22, Issue 9, 2013, Pages 533-542

  Kovshoff, Hanna ^a   Vrijens, May ^b   Thompson, Margaret ^a   Yardley, Lucy ^a   Hodgkins, Paul ^c   Sonuga Barke, Edmund J S ^a,d   Danckaerts, Marina ^b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b KU LEUVEN UNIVERSITY OF LEUVEN   (Belgium)

^c SHIRE   (United States)

^d GHENT UNIVERSITY   (Belgium)

Author keywords

ADHD; Attitudes; Clinical decision making; Prescribing; Questionnaire development

Indexed keywords

ARTICLE; ATTENTION DEFICIT DISORDER; BELGIUM; CLINICAL DECISION MAKING; HUMAN; INFLUENCES ON PRESCRIBING FOR ADHD QUESTIONNAIRE; INTERNAL CONSISTENCY; LONG TERM CARE; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PRESCRIPTION; PSYCHOTHERAPY; QUESTIONNAIRE; TREATMENT OUTCOME; UNITED KINGDOM;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DECISION MAKING; DRUG PRESCRIPTIONS; FEMALE; HUMANS; MALE; METHYLPHENIDATE; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 84883487946     PISSN: 10188827     EISSN: 1435165X     Source Type: Journal    
DOI: 10.1007/s00787-013-0393-y     Document Type: Article

References (40)

1. Barkley RA et al (2004) Young adult follow-up of hyperactive children: antisocial activities and drug use. J Child Psychol Psychiatry 45(2):195-211
2. Jensen PS et al (2001) ADHD comorbidity findings from the MTA study: comparing comorbid subgroups. J Am Acad Child Adolesc Psychiatry 40(2):147-158
3. Kadesjo B, Gillberg C (2001) The comorbidity of ADHD in the general population of Swedish school age children. J Child Psychol Psychiatry 42:487-492
4. Thompson MJ et al (2004) Profiles, co-morbidity and their relationship to treatment of 191 children with AD/HD and their families. Eur Child Adolesc Psychiatry 13(4):234-242
5. Barkley RA, Fischer M, Smallish L, Fletcher K (2006) Young adult outcome of hyperactive children: adaptive functioning in major life activities. J Am Acad Child Adolesc Psychiatry 45(2):192-202
6. Barkley RA (2002) International consensus statement on ADHD. January 2002. Clin Child Fam Psychol Rev 5(2):89-111
7. Chitsabesan P et al (2006) Mental health needs of young offenders in custody and in the community. Br J Psychiatry 188:534-540
8. Gadow KD et al (2002) Tics and psychiatric comorbidity in children and adolescents. Dev Med Child Neurol 44(5):330-338
9. Johnston C, Mash EJ (2001) Families of children with attention-deficit/ hyperactivity disorder: review and recommendations for future research. Clin Child Fam Psychol Rev 4(3):183-207
10. Swensen AR et al (2003) Attention-deficit/hyperactivity disorder: increased costs for patients and their families. J Am Acad Child Adolesc Psychiatry 42(12):1415-1423
11. Pelham WE, Foster EM, Robb JA (2007) The economic impact of attention-deficit/hyperactivity disorder in children and adolescents. J Pediatr Psychol 32(6):711-727
12. Excellence, N.I.f.C., Health NCCfM. Attention deficit hyperactivity disorder. Diagnosis and management of ADHD in children, young people, and adults (full NICE guideline) (2008)
13. Network SIG (2009) Management of attention deficit and hyperkinetic disorders in children and young people. SIGN, Edinburgh
14. Taylor E et al (2004) European clinical guidelines for hyperkinetic disorder - first upgrade. Eur Child Adolesc Psychiatry 13(Suppl 1):I7-I30
15. Subcommittee on Attention-Deficit/Hyperactivity Disorder, S.C.O.Q.I. and Management, ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Pediatrics (2011)
16. Pliszka S (2007) Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 46(7):894-921
17. Santosh PJ, Taylor E (2000) Stimulant drugs. Eur Child Adolesc Psychiatry 9(Suppl 1):I27-I43
18. Greenhill LL, Findling RL, Swanson JM (2002) A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 109(3):E39
19. Greenhill L et al (2006) Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry 45(11):1284-1293
20. Biederman J et al (2009) Do stimulants protect against psychiatric disorders in youth with ADHD? A 10-year follow-up study. Pediatrics 124(1):71-78
21. Jensen DM et al (1999) Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder: the Multimodal Treatment Study of children with Attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 56(12):1088-1096
22. Michelson D et al (2001) Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 108(5):E83-E83
23. Donnelly C et al (2009) Safety and tolerability of atomoxetine over 3 to 4 years in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry 48(2):176-185
24. Jain R et al (2011) Clonidine extended-release tablets for pediatric patients with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 50(2):171-179
25. Greenhill LL et al (2001) Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial. J Am Acad Child Adolesc Psychiatry 40(2):180-187
26. Banaschewski T et al (2006) Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. Eur Child Adolesc Psychiatry 15(8):476-495
27. Kovshoff H et al (2012) The decisions regarding ADHD management (DRAMa) study: uncertainties and complexities in assessment, diagnosis and treatment, from the clinician's point of view. Eur Child Adolesc Psychiatry 21(2):87-99
28. Banaschewski T et al (2008) Long-acting medications for the treatment of hyperkinetic disorders - a systematic review and European treatment guidelines. Part 2: a quantitative evaluation of long-acting medications. Z Kinder Jugendpsychiatr Psychother 36(2):97-106 (quiz 106-7)
29. Schachar R et al (2002) Attention-deficit hyperactivity disorder: critical apparaisal of extended treatment studies. Can J Psychiatry 47:337-348
30. Vitiello B (2001) Long-term effects of stimulant medications on the brain: possible relevance treatment of attention deficit hyperactivity disorder. J Child Psychol Psychiatry 11:25-34
31. Andersen SL (2005) Stimulants and the developing brain. Trends Pharmacol Sci 26:237-243
32. Grund T et al (2006) Influence of methylphenidate on brain development - an update of recent animal experiments. Behav Brain Funct 2:2
33. Pappadopulos E et al (2009) Medication adherence in the MTA: saliva methylphenidate samples versus parent report and mediating effect of concomitant behavioral treatment. J Am Acad Child Adolesc Psychiatry 48(5):501-510
34. Charach A et al (2008) A theoretical approach to medication adherence for children and youth with psychiatric disorders. Harv Rev Psychiatry 16(2):126-135
35. Coghill DR, Rhodes SM, Matthews K (2007) The neuropsychological effects of chronic methylphenidate on drug-naive boys with attention-deficit/ hyperactivity disorder. Biol Psychiatry 62(9):954-962
36. Barbaresi WJ et al (2007) Modifiers of long-term school outcomes for children with attention-deficit/hyperactivity disorder: does treatment with stimulant medication make a difference? Results from a population-based study. J Dev Behav Pediatr 28(4):274-287
37. Powers RL et al (2008) Stimulant treatment in children with attention-deficit/hyperactivity disorder moderates adolescent academic outcome. J Child Adolesc Psychopharmacol 18(5):449-459
38. Scheffler RM et al (2009) Positive association between attention-deficit/hyperactivity disorder medication use and academic achievement during elementary school. Pediatrics 123(5):1273-1279
39. Krause J (2008) SPECT and PET of the dopamine transporter in attention-deficit/hyperactivity disorder. Expert Rev Neurother 8(4):611-625
40. Volkow ND et al (2009) Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA 301(11):1148-1154